AstraZeneca Non-Executive Director retirement

Regulatory News Service

16 August 2017 07:00 BST

AstraZeneca announced that, on 31 August 2017, Bruce Burlington will retire as a Non-Executive Director of AstraZeneca PLC and as a member of the Audit Committee, the Nomination and Governance Committee, and from his role as Chairman of the Science Committee.

Dr Burlington joined the Board in 2010 and will have served for seven years when he steps down.

Leif Johansson, Chairman of AstraZeneca, said: “Bruce has been an exemplary Director who has made a significant contribution to the Board’s work over many years. We have valued his insightful and frank participation as a Board member, and Chairman of the Science Committee during a period of innovation-led transformation at AstraZeneca. His diligence and commitment to the work of the Audit Committee and the Nomination and Governance Committee should also be acknowledged. On behalf of all Board members, we will miss Bruce as a colleague and send him our very best wishes for the future.”

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit and follow us on Twitter @AstraZeneca.


Media Enquiries





Esra Erkal-Paler


+44 203 749 5638

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Matt Kent


+44 203 749 5906

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677




Investor Enquiries



Thomas Kudsk Larsen


+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan


+1 240 477 3771

Nick Stone


+44 203 749 5716

Christer Gruvris

Autoimmunity, neuroscience & infection

+44 203 749 5711

US Toll-Free


+1 866 381 7277

Adrian Kemp

Company Secretary, AstraZeneca PLC


  • Regulatory